A clinical-stage biotechnology company focused on developing immune-modulating therapies for autoimmune diseases, cancer, and other chronic conditions. Its pipeline includes biologic drug candidates designed to selectively regulate immune responses, with value largely tied to clinical trial outcomes...
2 members of Congress have disclosed 5 trades in Nektar Therapeutics (NKTR), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-12-30 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2018-06-21 | Josh Gottheimer | sell | $1K – $15K |
| 2018-06-06 | Josh Gottheimer | buy | $1K – $15K |
| 2018-05-25 | MICHAEL T. MCCAUL | buy | $1K – $15K |
| 2018-05-09 | MICHAEL T. MCCAUL | sell | $1K – $15K |